A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report(†)

BACKGROUND: A phase I trial of veliparib (ABT-888), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, and temozolomide (TMZ) was conducted in children with recurrent brain tumors to (i) estimate the maximum tolerated doses (MTDs) or recommended phase II doses (RP2Ds) of veliparib and TMZ; (ii) d...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Su, Jack M., Thompson, Patrick, Adesina, Adekunle, Li, Xiao-Nan, Kilburn, Lindsay, Onar-Thomas, Arzu, Kocak, Mehmet, Chyla, Brenda, McKeegan, Evelyn, Warren, Katherine E., Goldman, Stewart, Pollack, Ian F., Fouladi, Maryam, Chen, Alice, Giranda, Vincent, Boyett, James, Kun, Larry, Blaney, Susan M.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2014
Teme:
Pediatric Neuro-Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4232081/
https://ncbi.nlm.nih.gov/pubmed/24908656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou103
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items